| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910777423403321 |
|
|
Titolo |
International benchmarking of US immunology research / / Panel on International Benchmarking of US Immunology Research, Committee on Science, Engineering, and Public Policy, National Academy of Sciences, National Academy of Engineering, Institute of Medicine |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington, DC, : National Academy Press, 1999 |
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (60 pages) : illustrations |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Immunology - Research |
Immunity |
Immunochemistry |
Immunogenetics |
Benchmarking (Management) |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
""INTERNATIONAL BENCHMARKING OF US IMMUNOLOGY RESEARCH""; ""Copyright""; ""PREFACE""; ""CONTENTS""; ""EXECUTIVE SUMMARY""; ""1 INTRODUCTION""; ""1.1 HOW IMPORTANT IS IT FOR THE UNITED STATES TO LEAD IN IMMUNOLOGY RESEARCH?""; ""1.2 WHAT IS IMMUNOLOGY?""; ""1.3 IMMUNOLOGY AS AN ACADEMIC DISCIPLINE""; ""1.4 WHAT IS THE INTERNATIONAL NATURE OF IMMUNOLOGY?""; ""1.5 WHAT ARE SOME CAVEATS?""; ""1.6 PANEL CHARGE AND RATIONALE""; ""2 BENCHMARKING RESULTS""; ""2.1 METHODS""; ""2.1.1 Reputation Survey""; ""2.1.2 Citation Analysis""; ""2.1.3 Journal Publication Analysis""; ""2.2 RESULTS"" |
""2.2.1 Reputation Survey"" ""2.2.2 Citation Analysis""; ""2.2.3 Journal Publication Analysis""; ""2.3 SUMMARY""; ""3 KEY FACTORS""; ""3.1 FUNDING""; ""3.2 HUMAN RESOURCES""; ""3.3 INFRASTRUCTURE""; ""3.4 BIOTECHNOLOGY AND PHARMACEUTICAL FIRMS""; ""3.5 THE CLINICAL TRIAL""; ""4 LIKELY FUTURE POSITION""; ""4.1 FUNDING AND RESOURCE LIMITATIONS""; ""4.2 INCREASED COMPETITION FROM EUROPE AND OTHER COUNTRIES""; ""4.3 CLINICAL IMMUNOLOGY AND THE SHIFT |
|
|
|
|
|
|
|
|
|
|
TOWARD HMOS""; ""4.4 TRAINING OF US STUDENTS""; ""5 SUMMARY AND CONCLUSIONS"" |
""5.1 THE UNITED STATES IS THE WORLD LEADER IN ALL THE MAJOR SUBFIELDS OF IMMUNOLOGY BUT IS ONLY AMONG THE WORLD LEADERS IN""""5.2 FLEXIBILITY TO PURSUE ORIGINAL AND INNOVATIVE RESEARCH IDEAS HAS ATTRACTED BOTH DOMESTIC AND INTERNATIONAL HUMAN""; ""5.3 INDUSTRIAL INTERESTS HAVE FOSTERED MANY STRIKING BREAKTHROUGHS IN IMMUNOLOGY""; ""5.4 A SCARCITY OF LARGE-SCALE CLINICAL TRIALS IN IMMUNOLOGY CAN BE ATTRIBUTED TO SHORTAGES OF FUNDING AND OF QUALIFIED""; ""5.5 SHIFTING FEDERAL AND INDUSTRY PRIORITIES, A POTENTIAL REDUCTION IN ACCESS TO DOMESTIC AND FOREIGN TALENT, AND THE""; ""REFERENCES""""APPENDIX PANEL AND STAFF BIOGRAPHICAL INFORMATION""; ""STAFF"" |
|
|
|
|
|
| |